Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizoprionodon acutus. II. Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model.
The effect of scymnol on the development of lesions in a rat peripheral arterial occlusion model, involving injection of 5% lactic acid into the femoral artery, was investigated. In this model oral administration of scymnol significantly prevented edematous swelling and development of lower limb lesions, including gangrene, and also reduced changes in blood coagulation parameters, platelet aggregation and retention rate at a dose of 10 or 30 mg/kg. However, it had no effect on these clotting system functions in sham-operated rats at a dose of 10 mg/kg. The effects of scymnol were also compared with those of ticlopidine and argatroban. The findings suggest that scymnol may be clinically useful for preventing thrombotic peripheral arterial occlusive disorders. Its prophylactic action appears to be mainly due to its potent ability to protect against endothelial cell damage due to lactic acidosis.
Ishida
H
H
School of Pharmaceutical Science, University of Shizuoka, Yada, Japan.
Nakayasu
H
H
Nukaya
H
H
Tsuji
K
K
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives; D001157:Arterial Occlusive Diseases / Q000473:pathology / Q000517:prevention & control*; D001777:Blood Coagulation / Q000187:drug effects; D002777:Cholestanols / Q000494:pharmacology*; D018940:Elasmobranchii; D005342:Fibrinolysis / Q000187:drug effects; D008297:Male; D010875:Pipecolic Acids / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides; D013988:Ticlopidine / Q000494:pharmacology
D000991:Antithrombins; D002777:Cholestanols; D010875:Pipecolic Acids; D013449:Sulfonamides; C059448:scymnol sulfate ester; D001120:Arginine; C031942:argatroban; D013988:Ticlopidine